Health & Fitness
Tue, November 22, 2011
WAYNE, Pa.--([ BUSINESS WIRE ])--Ryan & Maniskas, LLP ([ www.rmclasslaw.com/cases/vrus ]) is investigating potential claims against the board of directors of Pharmasset, Inc. ("Pharmasset" or the "Company") (NASDAQ: VRUS) concerning possible breaches of fiduciary duty and other violations of law related to the Companyas efforts to sell Pharmasset to Gilead Sciences, Inc. in a transaction valued at approximately $11 billion.
Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by Companyas board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Pharmasset. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at [ rmaniskas@rmclasslaw.com ] or visit: [ www.rmclasslaw.com/cases/vrus ].
Under the terms of the transaction, Pharmasset shareholders will receive $137 for each share of Pharmasset stock they own.
If you own shares of Pharmasset and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: [ www.rmclasslaw.com/cases/vrus ]. You may also email Mr. Maniskas at [ rmaniskas@rmclasslaw.com ]. For more information about class action cases in general, please visit our website: [ www.rmclasslaw.com ].
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
